Early allograft dysfunction (EAD) following a liver transplant (LT) unequivocally portends adverse graft and patient outcomes, but a widely accepted classification or grading system is lacking.
T he success and durability of a liver transplant (LT), unequivocally the gold-standard treatment for all patients with irreversible liver failure, 1,2 critically depend on the function of the liver allograft. Early allograft dysfunction (EAD), a term used to describe initial poor function of the transplanted liver, represents the clinical phenotype of severe ischemia-reperfusion injury due to a variety of recipient, donor, and perioperative factors. [3] [4] [5] Not only has EAD been shown to result in inferior graft and patient survival following both cadaveric 6-8 and living donor LT, 9 but it has also been associated with short-term and long-term renal impairment and increased use of resources.
10,11
The prognostic importance of EAD is undeniable, but a universally accepted definition remains elusive. The earliest characterizations of EAD relied primarily on peak serum aminotransferase levels, which reflected graft injury, [12] [13] [14] and a subsequent functional definition proposed by Deschênes and colleagues 15 that incorporated posttransplant bilirubin level and prothrombin time to reflect the metabolic and synthetic functions of the allograft. In the Model for End-Stage Liver Disease (MELD) era, 16 Olthoff et al 6 have validated what is now the most widely used definition of EAD: the presence of 1 or more of 3 variables, including (1) a peak serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level higher than 2000 U/L (to convert to microkatals per liter, multiply by 0.167) within the first 7 postoperative days (PODs), (2) a serum bilirubin level of 10 mg/dL or higher (to convert to micromole per liter, multiply by 17.104) on POD 7, and (3) an international normalized ratio (INR) of 1.6 or higher on POD 7. Under this current definition, the binary categorization of all patients as either having or not having EAD fails to capture the continuum along which graft dysfunction manifests and results in an inability to discriminate patients with EAD who may experience early graft loss from most patients with EAD who may enjoy long-term graft failure-free survival. Recently, Pareja et al 17 reported on the Model for Early Allograft Function (MEAF) score (score range: 0 to 10, with higher scores indicating increasing hazard ratio [HR] for patient mortality at 3 months), which allows for the continuous grading of early allograft dysfunction and more accurately assesses graft function compared with the categorical classifications of EAD, but did not assess the model's accuracy in estimating graft failure.
With this study, we sought to develop a model-called the Liver Graft Assessment Following Transplantation (L-GrAFT)-based on posttransplant laboratory variables that allows for the individualized calculation of graft failure risk following LT and to compare the L-GrAFT's prognostic performance with the existing binary EAD definition and MEAF score.
Methods
We retrospectively reviewed a prospectively maintained transplant database to identify all adult patients (≥18 years of age) who underwent a primary LT and had available data on posttransplant laboratory studies, including serum AST, ALT, and total bilirubin levels, INR, and platelet counts. All LTs were per- The primary objective of this study was to develop a model allowing for individualized estimation of graft failure (ie, need for a retransplant or death) following an LT and then to compare its prognostic performance to the existing binary EAD definition 6 
Statistical Analysis
Continuous variables were summarized as median values and interquartile ranges (IQRs), and categorical variables were summarized as percentages. Graft failure-free survival and overall patient survival curves were computed using KaplanMeier methods and were compared using log-rank tests. Laboratory studies in the first 10 post-LT days were summarized to identify the variables most associated with graft failure, including measures of overall graft injury (AST and ALT levels), serum bilirubin level, INR, and platelet count. These candidate variables for AST and ALT levels included the overall 10-day mean (measured as the area under the curve [AUC]), maximum post-LT value, and rate of normalization
Key Points
Question What are the important posttransplant variables associated with graft outcomes after primary liver transplant?
Findings In this single-center analysis of 2008 adult recipients of a primary liver transplant, measures of posttransplant aspartate aminotransferase and bilirubin levels, international normalized ratios, and platelet counts were highly associated with 3-month graft-failure-free survival, which led to the creation of a risk scoring model called the Liver Graft Assessment Following Transplantation (L-GrAFT), designed for the continuous grading of early allograft dysfunction following a liver transplant.
Meaning The L-GrAFT risk score may serve as a tool for the standardized grading of early allograft function in transplant centers and as a highly accurate clinical end point in translational studies that aim to improve donor allograft quality and liver transplant outcomes.
(slope = unit change/d); for INR, the maximum post-LT INR and 10-day AUC; and for bilirubin level and platelet count, the total 10-day AUC, rate of normalization, change from pre-LT to last post-LT value, and post-LT days 7 and 10 values. All candidate laboratory measures were determined to be skewed on the original scale and, thus, were transformed to the logarithmic scale where they displayed a normal distribution.
Hazard rate ratios for time to graft failure were computed under a Cox regression model, allowing for interactions of each specified candidate variable with interval of follow-up time. The proportional hazards assumption for each variable was evaluated by plotting the HR for graft failure stratified by time interval of event (0-3 months, 3-6 months, 6-12 months, and >1 year). A model-the L-GrAFT-for calculating 3-month graft failure was developed using a logistic regression analysis based on the 18 post-LT candidate variables (eTable 1 in the Supplement). The initial model allowed for nonlinear effects using restricted cubic splines allowing for 3 knots (2 regression terms per variable), whereas the final multivariate model was selected using the backward stepwise procedure for variable selection and a liberal P < .15 as the retention criterion. The nonlinear effects observed on the log odds scale for the slope log AST, AUC log AST, and AUC log bilirubin were approximated by a quadratic curve and, hence, modeled by including quadratic terms to the logistic model.
Model accuracy was evaluated using receiver operating characteristic analysis under the logistic model, and the AUC was compared with the accuracy of the EAD definition and MEAF score, each of which was calculated for the UCLA cohort. The AUCs were compared between each pair of models nonparametrically using the method by DeLong et al. 18 Goodness of fit was assessed using the Hosmer- The most frequent underlying cause of liver disease was hepatitis C (38.5%), with diabetes, hypertension, and coronary artery disease in 25.9%, 29.6%, and 7.0% of patients, respectively. The median (IQR) recipient laboratory MELD score was 31 (25-38), with 46.1% of patients requiring pretransplant hospitalization, 31.8% requiring renal replacement therapy, 19.8% requiring mechanical ventilation, and 12.2% requiring vasopressors. Among the donors, the median (IQR) age was 41 (25-53) years, and 1294 (64.4%) were male. For this group, an LT was performed with a median (IQR) CIT of 404 (304-511) minutes, a median (IQR) WIT of 40 (35-47) minutes, and a median (IQR) transfusion of 11 (7-18) uPRBCs. At a median (IQR) follow-up of 36.8 (13.2-78.3) months, the overall patient and graft failure-free survival rates were 83% and 81% at year 1, 74% and 71% at year 3, and 69% and 65% at year 5, with an 11.1% (n = 222) incidence of 3-month graft failure (eFigure 1 in the Supplement). Of the 222 recipients, 180 (81.4%) died and 42 (18.9%) required a retransplant.
L-GrAFT Model Derivation
The ability of post-LT laboratory measures to prognosticate graft failure was first assessed using Cox regression analysis. The proportional hazards assumptions that each variable would have a constant association with graft failure over time was evaluated by plotting the HRs by interval of time for all 18 measures (eTable 1intheSupplement). As shown in Figure 1 for 7 of these variables included in the L-GrAFT model, the association of each laboratory variable with graft failure was most significant at 3 months but diminished significantly thereafter, consistently approaching nonsignificant HRs of 1 at 1 year. Specifically, the cumulative 10-day post-LT exposure and the rates of normalization of AST (AST log AUC [ Figure 1A ] and slope log AST [ Figure 1D ]) and bilirubin (bilirubin log AUC [ Figure 1B ] and slope log bilirubin [ Figure 1E ]) levels and platelet count (platelets log AUC [ Figure 1C ] and slope log platelets [ Figure 1F ]) and the maximum post-LT INR (log max INR [ Figure 1G ]) significantly affected graft failure at 3 months, but each approached nonsignificant HRs at 1 year.
Based on the results of the Cox regression, the final multivariate L-GrAFT model was constructed as a logistic regression evaluating the association of post-LT variables with the development of 3-month graft failure. Multivariate factors in 3-month graft failure are shown in Table 1 and include the total 10-day AST exposure (AUC 10 log AST: odds ratio [OR], 1.30 per SD increase; 95% CI, 1.05-1.60; P = .02) and early rate of normalization over 7 days (Slope 7 log AST: OR, 0.52 per SD decrease; 95% CI, 0.36-0.75; P = .02), maximum INR within the 10 posttransplant days (log maximum INR 10 : OR, 1.22 per SD increase; 95% CI, 1.02-1.45; P = .001), total 10-day bilirubin (AUC 10 log bilirubin: OR, 1.90 per SD increase; 95% CI, 1.54-2.34; P < .001) and rate of decrease (Slope 10 log bilirubin: OR, 0.62 per SD decrease; 95% CI, 0.51-0.75; P < .001), and total 10-day platelet count (AUC 10 log platelets: OR, 0.80 per SD increase; 95% CI, 0.65-0.9; P = .040) and rate of increase (Slope 10 log platelets: OR, 0.73 per SD increase; 95% CI, 0.60-0.88; P = .001). A modified L-GrAFT model based on 7-day post-LT variables (L-GrAFT 7 ) is shown in eTable 3 in the Supplement. 
Comparison of L-GrAFT Model With Existing Models of Early Allograft Dysfunction
The L-GrAFT model had good calibration (goodness of fit P = .41; eFigure 2 in the Supplement) with an excellent C statistic of 0.85 (internally validated C statistic of 0.84), which is significantly superior to the calculated MEAF score (C statistic, 0.70; P < .001) and EAD (C statistic, 0.68; P < .001) in determining 3-month graft failure in the entire cohort ( Figure 2A-C) , and excellent discrimination of risk when stratified by risk score groups ( Figure 2D-F) . The L-GrAFT risk score 
No EAD EAD
The Liver Graft Assessment Following Transplantation (L-GrAFT) score (A; C statistic, 0.85) had the highest AUROC statistically significantly superior to both the Model for Early Allograft Function (MEAF) score (B; C statistic, 0.70; P < .001) and the early allograft dysfunction (EAD) score (C; C statistic, 0.68; P < .001). The L-GrAFT model allowed for greater discrimination of 3-month graft-failure risk (D) compared with the MEAF score (E) and the binary EAD definition (F). Five risk groups (RGs) for 3-month graft failure for both L-GrAFT and MEAF were defined on the basis of risk score distribution, including (1) very low risk (Յ50th percentile), (2) low risk (>50th to Յ90th percentile), (3) moderate risk (>90th to Յ93.3 percentile), (4) moderate-to-high risk (>93.3 to Յ96.6 percentile), and (5) high risk (>96.6 percentile). GFFS indicates graft failure-free survival. where TBIL stands for total bilirubin and PLT stands for platelets.
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Post-LT Laboratory Profiles and Perioperative Characteristics Among L-GrAFT Risk Groups
The mean post-LT laboratory profile plots for the 5 L-GrAFT risk groups are shown in eFigure 3 in the Supplement. Compared with patients in lower-risk score groups (L-Graft 1 and 2), patients with higher L-Graft scores (L-Graft 3, 4, and 5) had increased overall AST (eFigure 3A in the Supplement) and ALT (eFigure 3B in the Supplement) levels, higher bilirubin levels with slower normalization (eFigure 3C in the Supplement), higher maximum INRs (eFigure 3D in the Supplement), and lower overall platelet counts with a slower rate of increase (eFigure3EintheSupplement). Evaluation of recipient, donor, and operative characteristics among L-GrAFT risk score groups are shown in 
Discussion
The durability of an LT in treating end-stage liver disease has created a critical shortage of donor organs, with far more patients in need of organs than are currently available. Use of extended criteria donors as a strategy to expand the donor pool may be effective in mitigating waitlist mortality, 19 but use of marginal grafts for an ever-increasing population of higher-acuity recipients risks the development of EAD, 2, 20 which negatively affects post-LT outcomes. 21, 22 With an increasing number of translational studies aiming to ameliorate the ischemia-reperfusion injury responsible for EAD, [23] [24] [25] [26] [27] it is critical to have a reliable measure of EAD that allows for comparison of meaningful graft-related outcomes across all transplant centers. Based on our analysis of more than 2000 patients who underwent primary LT, we developed the LGrAFT risk score that allows for a highly accurate, individualized calculation of 3-month graft failure.
Our L-GrAFT model incorporates 10 post-LT days of serum AST levels, a marker of graft injury, and the INR and bilirubin levels as measures of graft synthetic and metabolic functions. Most previous definitions of EAD have incorporated these variables (eg, maximum value within 3-7 days for the serum transaminase level and the INR, as well as the maximum value at day 3 or 7 for the bilirubin level) 6,12-15,17 as a static measure within a specified post-LT time frame. However, to our knowledge, the L-GrAFT model is the first comprehensive measure of EAD to also take into account the rate of change (slope) and trend in these variables. We show that faster normalization of both serum AST and bilirubin levels affect superior graft survival, independent of the absolute arbitrary values that have been used in previous models. For example, the existing binary definition would categorize all patients with a bilirubin level of 10 mg/dL or higher on POD 7 as having EAD; however, there is clearly a difference in graft function between a patient with a pretransplant bilirubin level of 40 mg/dL whose bilirubin is normalizing and a patient with liver cancer with a physiological MELD 7 who has a normal pretransplant bilirubin level and has developed significant cholestasis 1 week following LT. In addition, the total exposure (AUC) of AST or bilirubin over 10 days was more of a determinant of graft failure than any specific maximum or ultimate value, presumably because it reflects an average measure of graft assessment over time. Finally, to our knowledge, our L-GrAFT risk score is the first to incorporate postoperative platelet counts into a measure of EAD, with lower post-LT platelet counts and slower rates of increase highly associated with greater post-LT graft failure. Our findings are consistent with those in recent reports demonstrating an association with low postoperative platelet counts and delayed liver function following partial hepatectomy, 28 as well as increased post-LT complications and decreased 90-day graft and patient survival following LT. The mathematical formula for calculating L-GrAFT risk score can be found in the Results section. The L-GrAFT scores corresponding to the 5 risk groups are as follows: (1) The L-GrAFT risk score, as a dynamic assessment of the graft over 10 days, demonstrated far superior discrimination of post-LT graft failure compared with both the EAD definition and the MEAF score. Based on the binary definition, 30.4% patients in our cohort were characterized as having EAD, with a modest discrimination of 3-month graft failure (AUC, 0.68) when comparing patients with EAD (17.5%) with patients without EAD (4.6%). Conversely, the individualized calculation of 3-month graft failure along a continuum of L-GrAFT risk scores (AUC, 0.85) allowed for significantly superior discrimination of risk compared with both the EAD definition (AUC, 0.68) and the MEAF score (AUC, 0.70), which itself was not superior to the binary EAD categorization. In fact, despite the MEAF score allowing for continuous grading of EAD severity and its external validation in an independent cohort of LT recipients, the authors of that study did not report the MEAF model's accuracy, limiting any objective assessment of added utility when it is compared with the EAD definition.
29,30
Another notable finding was that the magnitude of the association between post-LT laboratory variables and graft failure did not remain constant over time, with the largest association seen early (at 3 months) and subsequently diminishing with HRs universally approaching 1 after 12 months. This empirical rejection of the proportional hazards assumption was the primary reason we developed the L-GrAFT risk score as a logistic regression of 3-month graft failure. Not surprisingly, an examination of factors associated with higher L-GrAFT risk scores identified recipient acuity measures (ie, higher MELD scores, higher number of patients who underwent pretransplant renal replacement therapy, and greater need for intubation and vasopressors), as well as donor characteristics (increased age) and operative characteristics (higher CITs and uPRBC transfusions), that have strongly been associated with inferior graft outcomes. The well-established Survival Outcomes Following Liver Transplantation 31 and Balanced Assessment of Risk scores, 32 which model 3-month patient survival, have identified similar recipient, donor, and operative characteristics, but both scores demonstrate modest model accuracy (C statistic, 0.70) compared with the L-GrAFT risk score (C statistic, 0.85). This finding perhaps is not unexpected given that potentially unknowable pretransplant variables not included in these models ultimately affect the early graft func- 
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Limitations
This study has several limitations. The requirement for 10 days of post-LT variables may be more cumbersome compared with the requirement for other measures of EAD that rely on only 3 or 7 days of laboratory values; however, the significantly superior accuracy of the L-GrAFT in determining 3-month graft failure may justify the inclusion of more data points. In fact, the evaluation of the L-GrAFT score using only 7 days of post-LT variables nonetheless yielded a C statistic of 0.83, which is far superior to that achieved by existing models. The actual LGrAFT score is mathematically complicated, but an online LGrAFT calculator allows transplant providers to simply enter the post-LT laboratory values to obtain an estimated risk of 3-month graft failure without the need for complex calculations. Finally, although our L-GrAFT model showed excellent accuracy in determining 3-month graft failure in a cohort of high-acuity recipients in a transplant center in the western United States, its results may not necessarily be generalizable to transplant recipients in different practice environments. To this end, external validation of the L-GrAFT risk score is necessary to establish its role as an important tool for grading early allograft function across all transplant centers and practice environments.
Conclusions
The L-GrAFT risk score model allows for highly accurate, individualized risk estimation of 3-month graft failure following LT and is superior to the existing binary EAD classification and MEAF score. External multicenter validation may lead to the adoption of the L-GrAFT as a tool for determining the need for a retransplant and for establishing a standardized grading system of early allograft function across transplant centers. Finally, with innumerable translational studies aiming to improve the quality of marginal grafts to expand the donor pool, or to modify recipient factors to mitigate ischemia-reperfusion injury, the L-GrAFT score, as a highly accurate measure of early graft failure, may serve as an excellent clinical end point by which to measure and compare the efficacy of interventions. quartile with exception of ALT, AST, and bilirubin slope which report quartile 1 compared to highest quartile, HR -hazard ratio, CI -confidence interval, ALT -alanine aminotransferase, AST -aspartate aminotransferase, INR -international normalized ratio, PLT -platelets,  -for ALT, AST, and bilirubin, rate of decrease is modeled, with more negative rates (Q1) having lower hazard compared to less negative rates (Q4) of normalization,  -for PLT, rate of increase is modeled, with faster rates of increase (Q4) having less hazard than lower rates of increase (Q1) 
